Zions Bancorporation N.A. Sells 69 Shares of Danaher Co. (NYSE:DHR)

Zions Bancorporation N.A. cut its position in shares of Danaher Co. (NYSE:DHR) by 3.6% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,848 shares of the conglomerate’s stock after selling 69 shares during the quarter. Zions Bancorporation N.A.’s holdings in Danaher were worth $514,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. KBC Group NV boosted its stake in Danaher by 36.8% during the third quarter. KBC Group NV now owns 282,386 shares of the conglomerate’s stock worth $78,508,000 after acquiring an additional 76,017 shares in the last quarter. Kovack Advisors Inc. boosted its position in shares of Danaher by 3.4% in the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after purchasing an additional 41 shares in the last quarter. Oppenheimer & Co. Inc. grew its stake in shares of Danaher by 0.5% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 25,120 shares of the conglomerate’s stock worth $6,984,000 after buying an additional 116 shares during the last quarter. Pinnacle Financial Partners Inc increased its position in Danaher by 1.2% during the 3rd quarter. Pinnacle Financial Partners Inc now owns 61,130 shares of the conglomerate’s stock valued at $16,995,000 after buying an additional 706 shares in the last quarter. Finally, Simmons Bank raised its stake in Danaher by 3.5% during the third quarter. Simmons Bank now owns 25,966 shares of the conglomerate’s stock valued at $7,219,000 after buying an additional 883 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Down 3.7 %

NYSE DHR opened at $230.51 on Friday. The stock’s 50-day moving average price is $262.91 and its 200-day moving average price is $260.49. The company has a market capitalization of $166.49 billion, a P/E ratio of 45.00, a price-to-earnings-growth ratio of 4.44 and a beta of 0.85. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher Co. has a 52 week low of $206.30 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the business posted $2.02 earnings per share. The company’s revenue was up 3.1% on a year-over-year basis. On average, equities research analysts predict that Danaher Co. will post 7.51 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 20.61%.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 18.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 11.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on DHR shares. Barclays reduced their price target on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Royal Bank of Canada reduced their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a research note on Thursday, October 31st. UBS Group reduced their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Finally, Leerink Partners upped their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.